Biohealthcare specialist company DXVX has hit the upper price limit (the highest daily price limit).
As of 2:42 PM on the 18th, DXVX is trading at 2,195 KRW, up 506 KRW (29.96%) from the previous trading day.
This rise appears to be driven by news accelerating the development of an oral obesity treatment.
On the same day, DXVX announced that based on previous research results confirming superiority over control substances in late-stage clinical trials, it is currently optimizing its oral GLP (glucagon-like peptide)-1 obesity drug candidate.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
